- Arrangør
- Bioteknologirådet, Bergen Centre for Ethics and Priority Setting in Health, University of Bergen
- Dag
- Onsdag 14.8 2024 10:00 - 11:00
- Arrangementstype
- Debatt
- Tema
- Helse
- Internasjonalt
- Språk
- English
- Sted
- Impact Hub Agder Arendal
- Vis i kart
- Antall plasser i lokalet
- 70
- Streaming
Gå til streamingsiden- Medvirkende
- Marianne Aasen, Head of Bioteknologirådet
- Ole Frithjof Norheim, Professor and Director of BCEPS UiB
- Lisa Sivertsen, Director, Department for Human Development, Norad – Norwegian Agency for Development Cooperation
- Ezekiel J. Emanuel, Special Advisor to the Director General, WHO, professor and Vice Provost, University of Pennsylvania and Workstream Lead BCEPS
- Eirik Mofoss, Executive Director, Langsikt, Centre for Long-Term Policy
- Pakwanja D. Twea, PhD Research Fellow, BCEPS, UiB
- Lumbwe Chola, Associate Professor, UiO and Ghana NCD Project Lead BCEPS UiB
- Eirik Joakim Tranvåg, Senior Advisor, Bioteknologirådet
- Mette Risa, Head of Communciation, Bioteknologirådet
- Kontaktperson
- Anne Marit Ryen, Bioteknologirådet, 41681490
- Nettside
- https://www.bioteknologiradet.no/arrangement/new-biotechnology-to-end-malaria-a-priority-for-norwegian-aid/
- Universell utforming
- Nei
- Miljøprofil
Ja, vi oppfyller Arendalsukas miljøkrav.
- Om arrangementet
Mosquito control programs using genetically modified mosquitoes and more efficient malaria vaccines signal a promising trajectory to end malaria. How should these new malaria measures be prioritized? Who should decide – and pay?
The malaria parasite is a significant global threat, with an annual toll of 250 million falling ill and 600,000 dying from the mosquito-borne disease. Djibouti and Uganda are about to initiate mosquito control programs using genetically modified mosquitoes. Additionally, new malaria vaccines being rolled-out in several African countries, including Cameroon and Burkina Faso.
These biotech advancements signal a promising trajectory for global health, with some foreseeing the potential eradication of malaria. However, biotechnology breakthroughs bring new ethical challenges.
Bioteknologirådet (The Norwegian Biotechnology Board) and the Bergen Centre for Ethics and Priority Setting in Health (BCEPS) at the University of Bergen invite national and international experts to deliberate Norway's role as a global health actor. Is this Norway's opportunity to lead the charge in malaria eradication, or is Norwegian aid funding best allocated elsewhere?